Glycometabolic status and acute myocardial infarction: has the time come for glucose-insulin-(potassium) therapy?
Glucose-insulin-potassium infusion as a metabolic therapy was first advocated for the management of acute myocardial infarction (AMI) in 1960s. Over the subsequent decades, enthusiasm for its use has been patchy, especially with the availability of other effective treatments such as reperfusion therapy for AMI. Several clinical studies in the mid-1990s revived the interest in the glycometabolic aspects of patients with AMI. The somewhat conflicting results of these recent studies have generated debate over the significance of the glycometabolic state following acute coronary occlusion and the role of insulin-based infusion therapy. Although most of the available evidence is in favour of an insulin-based therapy, there are still many aspects of this therapy that require clarification. More evidence will be required from further clinical trials before it is adopted in routine clinical practice.
D002314:Cardioplegic Solutions / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D016638:Critical Illness; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000401:mortality; D005947:Glucose / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D011188:Potassium / Q000627:therapeutic use*; D016896:Treatment Outcome
D002314:Cardioplegic Solutions; D007328:Insulin; C030396:glucose-insulin-potassium cardioplegic solution; D005947:Glucose; D011188:Potassium